Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
Open accessAbstract
In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05–0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47–2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Omicron IAR estimates over time were lower than those reported in South Africa, Denmark, Navarre, Spain, and British Columbia, Canada.
“Our Omicron IAR estimates over time were lower than those reported in South Africa (58% in urban areas by April 2022)20, Denmark (66% by March 2022)21, Navarre, Spain (up to 59% by May 2022)22 and British Columbia, Canada (up to 61% by July–August 2022)23”
From Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population (2023) · cites this paper as [22]
The Seroprevalence section reports anti-N antibodies in 58.9% of the Navarre sample in May 2022, supporting the cited figure of about 59%. It does not report that figure as an Omicron infection attack rate: anti-N antibodies indicate prior SARS-CoV-2 infection without identifying the variant. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551 · see citing works
Jones, J. M., Stone, M., Sulaeman, H., Fink, R. V., Dave, H., Levy, M. E., Di Germanio, C., Green, V., Notari, E., Saa, P., et al. (2021) · JAMA · doi:10.1001/jama.2021.15161 · Cited by 201 · see citing works
Flagged first, then by citations
Research works printed but not linked: 8
- World Health Organization (WHO). Interim statement on hybrid immunity and increasing population seroprevalence rates. Geneva: WHO; 1 Jun 2022. Available from: https://www.who. int/news/item/01-06-2022-interim-statement-on-hybrid- immunity-and-increasing-population-seroprevalence-rates 3. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021;26(50):2101147. https://doi.org/10.2807/1560-7917. ES.2021.26.50.2101147 PMID: 34915975 · DOI
- Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1):907. https://doi.org/10.1038/s41467-022-28527-x PMID: 35173150 · DOI
- Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Guevara M, Fernández-Huerta M, Burgui C, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021;26(39):2100894. https://doi.org/10.2807/1560-7917. ES.2021.26.39.2100894 PMID: 34596016 · DOI
- Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022;386(13):1207-20. https://doi.org/10.1056/NEJMoa2118691 PMID: 35172051 · DOI
- Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;22(6):781- 90. https://doi.org/10.1016/S1473-3099(22)00143-8 PMID: 35366962 · DOI
- Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26(21):2100438. https://doi.org/10.2807/1560- 7917.ES.2021.26.21.2100438 PMID: 34047271 · DOI
- Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez- Baz I, et al. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/ EEA countries, October 2021 to March 2022. Euro Surveill. 2022;27(30):2200551. https://doi.org/10.2807/1560-7917. ES.2022.27.30.2200551 PMID: 35904059 · DOI
- Suarez Castillo M, Khaoua H, Courtejoie N. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. Euro Surveill. 2022;27(16):2200250. https://doi.org/10.2807/1560- 7917.ES.2022.27.16.2200250 PMID: 35451363 License, supplementary material and copyright License, supplementary material and copyright · DOI
Cited by
Sorted by citations
Lau, J. J., Cheng, S. M. S., Leung, K., Lee, C. K., Hachim, A., Tsang, L. C. H., Yam, K. W. H., Chaothai, S., Kwan, K. K. H., Chai, Z. Y. H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02219-5 · Cited by 198 · see citing works
- Authors
- Castilla, J., Lecea, Ó., Martín Salas, C., Quílez, D., Miqueleiz, A., Trobajo-Sanmartín, C., Navascués, A., Martínez-Baz, I., Casado, I., Burgui, C., Egüés, N., Ezpeleta, G., & Ezpeleta, C.
- Affiliations
- Instituto de Salud Pública de Navarra (ES)
- Servicio Navarro de Salud (ES)
- Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain
- Hospital Reina Sofía, Tudela, Spain
- Navarre Institute of Health Research (ES)
- Navarre Institute for Health Research (IdiSNA), Pamplona, Spain
- ORCID
- Venue
- Eurosurveillance
- Published
- 2022-08-18
- Volume
- 27
- Issue
- 33
- ISSN
- 1025-496X (ISSN-L)
- 1560-7917
- PMC
- PMC9389855
- OpenAlex
- W4292485500
- Cited by
- 31
- References
- 2
- Citations by year
- 2025: 8 · 2024: 7 · 2023: 12 · 2022: 4
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Eurosurveillance (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Instituto de Salud Carlos III
- European Regional Development Fund
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, anti-nucleocapsid antibodies, anti-spike antibodies, Omicron variant, hybrid immunity, natural infection, Navarre
- MeSH terms
- COVID-19, SARS-CoV-2, Antibodies, Viral, Humans, Spain, Seroepidemiologic Studies, Nucleocapsid Proteins, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
